Exploring molecular profiles in inflammatory skin diseases
Systematic Profiling of Anti-cytokine Signatures in the Treatment of Chronic Inflammatory Skin Disorders
This study is trying to see how different biological factors in the skin affect psoriasis and atopic dermatitis, and how treatments can help manage these conditions better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Sex | All |
| Sponsor | University Hospital Schleswig-Holstein Academic / other |
| Locations | 1 site (Kiel) |
| Trial ID | NCT03358693 on ClinicalTrials.gov |
What this trial studies
This observational pilot project aims to utilize a systems medicine approach to identify regulatory networks and their disruptions in psoriasis and atopic dermatitis. By integrating and modeling data across various cellular levels and time, the study will analyze the effects of licensed biologics during routine care on disease control. It involves ultra-deep phenotyping and molecular characterization of patients to generate insights into disease pathways and extract molecular signatures that correlate with clinical severity scores. The study will focus on differentially expressed genes and other molecular signatures associated with disease activity and progression.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with chronic psoriasis or atopic dermatitis who are receiving systemic therapy.
Not a fit: Patients who have recently used immunosuppressive therapies or topical treatments may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of inflammatory skin diseases, potentially enhancing treatment outcomes for patients.
How similar studies have performed: Other studies utilizing systems biology approaches have shown promise in identifying disease mechanisms, suggesting potential for success in this novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Ability to provide written informed consent and comply with the protocol * Dermatologist-diagnosed chronic inflammatory skin disease * Subject receives systemic therapy within routine care (in-label use of biologics) Exclusion Criteria: * Subject is unable to provide written informed consent or comply with the protocol. * Having used immunosuppressive/immunomodulating therapy or phototherapy within 4 weeks before the baseline visit. * Treatment of selected skin areas to be examined with topical corticosteroid or topical calcineurin inhibitor within 1 week before the baseline visit.
Where this trial is running
Kiel
- Department of Dermatology, University Hospital Schleswig Holstein, Campus Kiel — Kiel, Germany (Recruiting)
Study contacts
- Principal investigator: Stephan Weidinger, MD — Department of Dermatology, university Hospital Schleswig-Holstein, Campus Kiel
- Study coordinator: Stephan Weidinger, MD
- Email: sweidinger@dermatology.uni-kiel.de
- Phone: 004943150021101
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.